BC
GNCA

Birchview Capital’s Genocea Biosciences, Inc. GNCA Stock Holding History

Birchview Capital’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,625
Closed -$147K – 58
2018
Q3 		$147K Hold
23,625
– – 0.09% 50
2018
Q2 		$162K Hold
23,625
– – 0.11% 48
2018
Q1 		$198K Buy
23,625
+18,750
+385% +$156K 0.13% 43
2017
Q4 		$45K Hold
4,875
– – 0.03% 41
2017
Q3 		$57K Hold
4,875
– – 0.03% 40
2017
Q2 		$204K Hold
4,875
– – 0.11% 32
2017
Q1 		$238K Hold
4,875
– – 0.13% 34
2016
Q4 		$161K Hold
4,875
– – 0.1% 39
2016
Q3 		$200K Hold
4,875
– – 0.12% 38
2016
Q2 		$160K Hold
4,875
– – 0.12% 38
2016
Q1 		$302K Buy
+4,875
New +$155K 0.22% 31

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Birchview Capital's GNCA Position: Q4 2018 in Review

Birchview Capital sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2018, closing a stake of 23,625 shares — an estimated $147K sold.

Birchview Capital first reported a position in GNCA in Q1 2016 and held it in 11 quarters. The position peaked at $302K in Q1 2016. 43 funds tracked by Wall St. Rank hold GNCA as of Q4 2018.

  • Birchview Capital reported no remaining Genocea Biosciences, Inc. position as of Q4 2018 after selling out during the quarter.
  • Birchview Capital sold 23,625 Genocea Biosciences, Inc. shares in Q4 2018, an estimated $147K.
  • Birchview Capital first reported a position in Genocea Biosciences, Inc. in Q1 2016 and held it in 11 quarters.
  • Birchview Capital's Genocea Biosciences, Inc. position peaked at $302K in Q1 2016.
  • 43 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2018.

Based on Birchview Capital's 13F filing for Q4 2018, filed 6 Feb 2019.